372 related articles for article (PubMed ID: 29627952)
1. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.
Katz LM; Hielscher T; Liechty B; Silverman J; Zagzag D; Sen R; Wu P; Golfinos JG; Reuss D; Neidert MC; Wirsching HG; Baumgarten P; Herold-Mende C; Wick W; Harter PN; Weller M; von Deimling A; Snuderl M; Sen C; Sahm F
Acta Neuropathol; 2018 Jun; 135(6):955-963. PubMed ID: 29627952
[TBL] [Abstract][Full Text] [Related]
2. The substantial loss of H3K27me3 can stratify risk in grade 2, but not in grade 3 meningioma.
Jung M; Kim SI; Lim KY; Bae J; Park CK; Choi SH; Park SH; Won JK
Hum Pathol; 2021 Sep; 115():96-103. PubMed ID: 34186055
[TBL] [Abstract][Full Text] [Related]
3. Impact of H3K27 trimethylation loss in meningiomas: a meta-analysis.
Cello G; Patel RV; McMahon JT; Santagata S; Bi WL
Acta Neuropathol Commun; 2023 Jul; 11(1):122. PubMed ID: 37491289
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A
Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689
[TBL] [Abstract][Full Text] [Related]
5. Altered expression of epigenetic modifiers EZH2, H3K27me3, and DNA methyltransferases in meningiomas - prognostic biomarkers for routine practice.
Samal S; Patnaik A; Sahu F; Purkait S
Folia Neuropathol; 2020; 58(2):133-142. PubMed ID: 32729292
[TBL] [Abstract][Full Text] [Related]
6. Molecular biological determinations of meningioma progression and recurrence.
Linsler S; Kraemer D; Driess C; Oertel J; Kammers K; Rahnenführer J; Ketter R; Urbschat S
PLoS One; 2014; 9(4):e94987. PubMed ID: 24722350
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
[TBL] [Abstract][Full Text] [Related]
8. Loss of H3K27me3 in meningiomas.
Nassiri F; Wang JZ; Singh O; Karimi S; Dalcourt T; Ijad N; Pirouzmand N; Ng HK; Saladino A; Pollo B; Dimeco F; Yip S; Gao A; Aldape KD; Zadeh G;
Neuro Oncol; 2021 Aug; 23(8):1282-1291. PubMed ID: 33970242
[TBL] [Abstract][Full Text] [Related]
9. DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.
Menghi F; Orzan FN; Eoli M; Farinotti M; Maderna E; Pisati F; Bianchessi D; Valletta L; Lodrini S; Galli G; Anghileri E; Pellegatta S; Pollo B; Finocchiaro G
Oncologist; 2011; 16(10):1440-50. PubMed ID: 21948653
[TBL] [Abstract][Full Text] [Related]
10. H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort.
Behling F; Fodi C; Gepfner-Tuma I; Kaltenbach K; Renovanz M; Paulsen F; Skardelly M; Honegger J; Tatagiba M; ; Schittenhelm J; Tabatabai G
Neuro Oncol; 2021 Aug; 23(8):1273-1281. PubMed ID: 33367841
[TBL] [Abstract][Full Text] [Related]
11. Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker.
Parada CA; Osbun JW; Busald T; Karasozen Y; Kaur S; Shi M; Barber J; Adidharma W; Cimino PJ; Pan C; Gonzalez-Cuyar LF; Rostomily R; Born DE; Zhang J; Ferreira M
Clin Cancer Res; 2020 Jan; 26(1):193-205. PubMed ID: 31615938
[TBL] [Abstract][Full Text] [Related]
12. Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas.
Pérez-Magán E; Rodríguez de Lope A; Ribalta T; Ruano Y; Campos-Martín Y; Pérez-Bautista G; García JF; García-Claver A; Fiaño C; Hernández-Moneo JL; Mollejo M; Meléndez B
Neuro Oncol; 2010 Dec; 12(12):1278-90. PubMed ID: 20685720
[TBL] [Abstract][Full Text] [Related]
13. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
[TBL] [Abstract][Full Text] [Related]
14. Loss of H3K27me3 expression enriches in recurrent grade 1&2 meningiomas and maintains as a biomarker stratifying progression risk.
Hua L; Ren L; Wu Q; Deng J; Chen J; Cheng H; Wang D; Chen H; Xie Q; Wakimoto H; Gong Y
J Neurooncol; 2023 Jan; 161(2):267-275. PubMed ID: 36329368
[TBL] [Abstract][Full Text] [Related]
15. Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes.
Durand A; Champier J; Jouvet A; Labrousse F; Honnorat J; Guyotat J; Fèvre-Montange M
Clin Neuropathol; 2008; 27(5):334-45. PubMed ID: 18808065
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic changes underlie the aggressiveness of histologically benign meningiomas that recur.
San-Miguel T; Navarro L; Megías J; Muñoz-Hidalgo L; Gil-Benso R; Roldán P; López-Ginés C; Cerdá-Nicolás M
Hum Pathol; 2019 Feb; 84():105-114. PubMed ID: 30261191
[TBL] [Abstract][Full Text] [Related]
17. Mutational patterns and regulatory networks in epigenetic subgroups of meningioma.
Paramasivam N; Hübschmann D; Toprak UH; Ishaque N; Neidert M; Schrimpf D; Stichel D; Reuss D; Sievers P; Reinhardt A; Wefers AK; Jones DTW; Gu Z; Werner J; Uhrig S; Wirsching HG; Schick M; Bewerunge-Hudler M; Beck K; Brehmer S; Urbschat S; Seiz-Rosenhagen M; Hänggi D; Herold-Mende C; Ketter R; Eils R; Ram Z; Pfister SM; Wick W; Weller M; Grossmann R; von Deimling A; Schlesner M; Sahm F
Acta Neuropathol; 2019 Aug; 138(2):295-308. PubMed ID: 31069492
[TBL] [Abstract][Full Text] [Related]
18. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
[TBL] [Abstract][Full Text] [Related]
19. Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.
Everson RG; Hashimoto Y; Freeman JL; Hodges TR; Huse J; Zhou S; Xiu J; Spetzler D; Sanai N; Kim L; Kesari S; Brenner A; De Monte F; Heimberger A; Raza SM
J Neurooncol; 2018 Sep; 139(2):469-478. PubMed ID: 29846894
[TBL] [Abstract][Full Text] [Related]
20. Tumor grade-related NDRG2 gene expression in primary and recurrent intracranial meningiomas.
Skiriute D; Tamasauskas S; Asmoniene V; Saferis V; Skauminas K; Deltuva V; Tamasauskas A
J Neurooncol; 2011 Mar; 102(1):89-94. PubMed ID: 20607352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
